Swiss Liver Venous Thrombosis Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-03-18

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Liver Venous Thrombosis Study is a prospective observational cohort study aimed at collecting clinical data, patient reported outcomes and biological samples of all patients who have been newly and previously diagnosed with liver venous thrombosis in one of the participating hospitals in- and out-patient clinics of the participating centers in Switzerland. All new patients diagnosed with liver venous thrombosis or patients who are currently being treated in one of the participating centers, will be asked to participate in the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

INvestigating SIGnificant Health TrendS in the Management of Superficial Vein Thrombosis

NCT02699151

Superficial Vein Thrombosis

COMPLETED

Evaluation of Patients With Vena Cava Inferior Thrombosis

NCT00631423

Inferior Vena Cava Thrombosis Venous Thromboembolism

COMPLETED

Bern Venous Stent Registry

NCT02433054

Post-thrombotic Syndrome

COMPLETED

Study on Inferior Vena Cava Thrombosis

NCT04470986

Inferior Vena Cava Thrombosis

UNKNOWN

Venous Pressure Measurement of the Great Saphenous Vein Using Controlled Compression Ultrasound in Healthy Persons and Patients With Chronic Venous Disease as a New Non Invasive Method for Investigation of the Pathophysiology in Primary Varicose Veins

NCT01000909

Chronic Venous Insufficiency

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background

Outcome measures:

Primary: Liver venous thrombosis recanalization

Secondary: Thrombosis progression, Overall mortality, Major bleeding, Ascites

Objective

* To start a prospective observational cohort study of Liver Venous Thrombosis patients in Switzerland from their primary diagnosis and already diagnosed patients.
* To examine long-term medical outcomes in patients with liver venous thrombosis in Switzerland by defining incidence, risk factors and treatment results
* To prospectively collect data on medical history, serious comorbidities, baseline clinical parameters, imaging results, pathology results, tumor characteristics, treatment, treatment outcomes, hospital stays, interventions and complications.
* To store in a biobank blood and biological samples, obtained during routine practice

Methods

N/A

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Observational Study

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with Liver Venous Thrombosis

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Admitted in hospital or attend outpatient clinic
* Objectively confirmed portal vein thrombosis and/or hepatic vein thrombosis
* Budd-Chiari-Syndrome (BCS), Non-Cirrhotic Intrahepatic Portal Hypertension (NCIPH), Sinusoidal Obstructive Syndrome (SOS), Other Vascular Diseases (Hepatoportal Sclerosis (HC), Nodular Regenerative Hyperplasia (NRH), Obliterative Portal Venopathy (OPV) or Idiopathic Portal Hypertension (IPH))
* Subjects willing to provide informed consent

Exclusion Criteria

* Thrombosis limited to mesenteric or splenic vein
* Inability to sign consent form
* Follow-up not possible
* Cardiovascular, tumoral, pulmonary comorbidity with life expectancy estimated to be less than 6 months
* Portal vein invasion by hepatocellular carcinoma

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No